| CAR T cells in solid tumors: challenges and opportunities F Marofi, R Motavalli, VA Safonov, L Thangavelu, AV Yumashev, ... Stem cell research & therapy 12, 1-16, 2021 | 442 | 2021 |
| Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients F Marofi, HS Rahman, ZMJ Al-Obaidi, AT Jalil, WK Abdelbasset, ... Stem Cell Research & Therapy 12, 1-23, 2021 | 176 | 2021 |
| The effects of oxygen–ozone therapy on regulatory T‐cell responses in multiple sclerosis patients S Tahmasebi, MT Qasim, MV Krivenkova, AO Zekiy, L Thangavelu, ... Cell biology international 45 (7), 1498-1509, 2021 | 162 | 2021 |
| Th17 and Treg cells function in SARS‐CoV2 patients compared with healthy controls A Sadeghi, S Tahmasebi, A Mahmood, M Kuznetsova, H Valizadeh, ... Journal of Cellular Physiology, 2020 | 159 | 2020 |
| Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID‐19 patients S Tahmasebi, MA El‐Esawi, ZH Mahmoud, A Timoshin, H Valizadeh, ... Journal of cellular physiology 236 (7), 5325-5338, 2021 | 132 | 2021 |
| Solid tumors challenges and new insights of CAR T cell engineering S Tahmasebi, R Elahi, A Esmaeilzadeh Stem cell reviews and reports 15, 619-636, 2019 | 88 | 2019 |
| Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells R Elahi, E Khosh, S Tahmasebi, A Esmaeilzadeh Frontiers in immunology 9, 363385, 2018 | 72 | 2018 |
| Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2 S Tahmasebi, BQ Saeed, E Temirgalieva, AV Yumashev, MA El-Esawi, ... Life Sciences 276, 119437, 2021 | 62 | 2021 |
| Exosome engineering in cell therapy and drug delivery S Sadeghi, FR Tehrani, S Tahmasebi, A Shafiee, SM Hashemi Inflammopharmacology 31 (1), 145-169, 2023 | 53 | 2023 |
| Chimeric antigen receptor-T cell therapy: Applications and challenges in treatment of allergy and asthma A Esmaeilzadeh, S Tahmasebi, SS Athari Biomedicine & Pharmacotherapy 123, 109685, 2020 | 52 | 2020 |
| The outlook for diagnostic purposes of the 2019‐novel coronavirus disease S Tahmasebi, E Khosh, A Esmaeilzadeh Journal of cellular physiology 235 (12), 9211-9229, 2020 | 43 | 2020 |
| CAR-T cell combination therapy: the next revolution in cancer treatment M Al-Haideri, SB Tondok, SH Safa, AH Maleki, S Rostami, AT Jalil, ... Cancer Cell International 22 (1), 365, 2022 | 38 | 2022 |
| Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy S Tahmasebi, R Elahi, E Khosh, E Abdolreza Clinical and Translational Oncology 22 (11), 2020 | 35 | 2020 |
| Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patients M Izadi, S Tahmasebi, I Pustokhina, AV Yumashev, T Lakzaei, ... Multiple Sclerosis and Related Disorders 46, 102466, 2020 | 34 | 2020 |
| Recent advances in antibody‐based immunotherapy strategies for COVID‐19 A Esmaeilzadeh, S Rostami, PM Yeganeh, S Tahmasebi, M Ahmadi Journal of Cellular Biochemistry, 2021 | 29 | 2021 |
| Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism F Marofi, S Tahmasebi, HS Rahman, D Kaigorodov, A Markov, ... Stem cell research & therapy 12, 1-21, 2021 | 25 | 2021 |
| Recent advances in non-small cell lung cancer targeted therapy; an update review M Araghi, R Mannani, A Heidarnejad maleki, A Hamidi, S Rostami, ... Cancer Cell International 23 (1), 162, 2023 | 24 | 2023 |
| Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2 M Ghaebi, S Tahmasebi, M Jozghorbani, A Sadeghi, L Thangavelu, ... Life sciences 277, 119503, 2021 | 23 | 2021 |
| Immune-based therapy for COVID-19 A Esmaeilzadeh, D Jafari, S Tahmasebi, R Elahi, E Khosh Coronavirus Disease-COVID-19, 449-468, 2021 | 22 | 2021 |
| IL-38 as an early predictor of the ischemic stroke prognosis MZ Rafie, A Esmaeilzadeh, A Ghoreishi, S Tahmasebi, E Faghihzadeh, ... Cytokine 146, 155626, 2021 | 19 | 2021 |
